Standout Papers

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastati... 1994 2026 2004 2015 8.3k
  1. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 (2001)
    Dennis J. Slamon, Brian Leyland‐Jones et al. New England Journal of Medicine
  2. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer (2007)
    Lyndsay N. Harris, Herbert A. Fritsche et al. Journal of Clinical Oncology
  3. The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women (1999)
    Steven R. Cummings, Stephen Eckert et al. JAMA
  4. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress (1994)
    Russell K. Portenoy, Howard T. Thaler et al. European Journal of Cancer
  5. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. (1996)
    José Baselga, Debu Tripathy et al. Journal of Clinical Oncology
  6. Tumor Self-Seeding by Circulating Cancer Cells (2009)
    Mi Young Kim, Thórdur Óskarsson et al. Cell
  7. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer (2003)
    I. Craig Henderson, Donald A. Berry et al. Journal of Clinical Oncology
  8. Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation (2002)
    Noah D. Kauff, Jaya M. Satagopan et al. New England Journal of Medicine
  9. A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis (2012)
    Swarnali Acharyya, Thórdur Óskarsson et al. Cell
  10. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17 (2005)
    Paul E. Goss, James N. Ingle et al. JNCI Journal of the National Cancer Institute
  11. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. (1998)
    José Baselga, Larry Norton et al. PubMed
  12. Exogenous Expression of N-Cadherin in Breast Cancer Cells Induces Cell Migration, Invasion, and Metastasis (2000)
    Rachel B. Hazan, Greg R. Phillips et al. The Journal of Cell Biology
  13. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer (2004)
    Kevin S. Hughes, Lauren A. Schnaper et al. New England Journal of Medicine
  14. Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin (2000)
    José Baselga, David G. Pfister et al. Journal of Clinical Oncology
  15. Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung (2011)
    Zvi Granot, Erik Henke et al. Cancer Cell
  16. Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers (1996)
    D. F. Hayes, Robert C. Bast et al. JNCI Journal of the National Cancer Institute
  17. Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals (2009)
    Xiang H.-F. Zhang, Qiongqing Wang et al. Cancer Cell
  18. Symptom prevalence, characteristics and distress in a cancer population (1994)
    Russell K. Portenoy, Howard T. Thaler et al. Quality of Life Research
  19. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer (2006)
    Donald A. Berry, Constance Cirrincione et al. JAMA
  20. A Gompertzian model of human breast cancer growth. (1988)
    Larry Norton PubMed
  21. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss (2015)
    Gayatri Arun, Sarah D. Diermeier et al. Genes & Development

Immediate Impact

4 by Nobel laureates 23 from Science/Nature 172 standout
Sub-graph 1 of 14

Citing Papers

A view on drug resistance in cancer
2019 StandoutNature
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2018 Standout
1 intermediate paper

Works of Larry Norton being referenced

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Growth Curve of an Experimental Solid Tumor Following Radiotherapy
1977
and 2 more

Author Peers

Author Last Decade Papers Cites
Larry Norton 29114 15708 7885 13531 528 49.6k
Daniel F. Hayes 25941 20441 9264 12718 407 45.3k
Eric P. Winer 35888 19716 13979 10467 730 55.0k
Clifford A. Hudis 23054 13808 6733 8120 509 38.8k
Martine Piccart 26838 16098 9035 12544 830 41.8k
Gary M. Clark 27959 14287 10472 13822 265 43.7k
Nancy E. Davidson 20153 12093 5604 17415 396 40.3k
William McGuire 15572 7785 6078 12397 470 41.0k
Mitch Dowsett 31319 24499 12269 15240 779 57.9k
Ian O. Ellis 27787 26157 6928 20054 971 58.9k
Anthony Howell 20676 14545 6456 12182 672 41.6k

All Works

Loading papers...

Rankless by CCL
2026